Attendee search 

Foncoo was founded in 1999, headquartered in Shenzhen, is a specialty pharmaceutical company with more than 20 years of experience focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases in China.
Our product portfolio covers a range of therapeutic areas including the treatment of psychiatry and neurology diseases, cardiovascular diseases, cancer diseases and Nutritional Medicine. 

Pharmaceutical company

Connexin Therapeutics Ltd. is a UK-based biopharmaceutical company specializing in the Discovery and development,, of drugs targeting connexins, initially for the prevention of vision loss and blindness associated with the eye disease known as glaucoma. While there are a variety of glaucoma subtypes, a common hallmark is the progressive loss of vision due to the gradual cell death in the retina and optic nerve triggered by elevated intraocular pressure. Many drugs are available to reduce intraocular pressure, yet none have been shown to directly protect cells in the retina or optic nerve, and hence prevent them from dying. Thus, vision loss inevitably occurs, even in well-treated patients, and severe vision impairment remains common in these patients.
Connexin Therapeutics raised ~£150,000 in Seed financing in early 2019. These funds are being used to synthesize and test novel small molecules in animal models of glaucoma. Selected results from these studies are presented in this document. These compounds are based on a molecule which has already demonstrated efficacy in mouse models of glaucoma. Thus, these data supplement and extend the work already published.
We are currently raising ~£2,000,000 to expand our synthesis and optimize our lead compounds. After ~8-10 quarters of work we anticipate having a library of patentable compounds which are highly selective for our target, backed by cell and animal data. We may also have a second compound which inhibits a different retinal target for a different set of conditions. Future financing rounds will take one or both leads into formulation development, safety studies, and clinical trials, while also fueling our expansion into other indications with this same mechanism of action.

NxR Biotechnologies is a boutique global consulting firm assisting life science companies and academic institutions conduct business development or investment initiatives. Particularly, NxR provides Looking for services for performing strategic, scientific, and commercial assessments; writing business plans; gathering competitive intelligence; and implementing entrepreneurship projects, partnership and in/Licensing-out of conventional or regenerative medicine products, and commercialization deals. Areas of focus encompass the pharmaceutical industry and the white biotechnology industry. In the pharmaceutical industry, NxR focuses on cell-based and gene-based therapeutics, nucleic acid therapeutics, and biologics, in oncology, neurodegenerative diseases, inflammation, and rare diseases. In the white biotechnology industry, areas of specialization comprise sustainable chemicals including biomass conversion, biofuels, and polymers, as well as high value-added fermentation products including amino acids, proteins, and pharmaceuticals. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups.

digital healthcare company

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Acne, Rosacea, and Actinic keratosis. LEO Pharma is continously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets.

LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.

To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for Licensing-in Assets for Global and Regional Rights for following:
(1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases
(2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities.
(3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets
(4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology

family office with investments in Europe, Asia and Latin America